Search | IOVS | ARVO Journals

iovs

Issues
Topics
For Authors
About
- Editorial Board

Journals Home

MANAGE ALERTS

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

To View More...

Purchase this article with an account.

or

Subscribe Now

Issues
Topics
For Authors
About
- Editorial Board

Narrow View

NARROW

Content Type

Meeting Abstract (14)
Journal Articles (1)

Journal

Investigative Ophthalmology & Visual Science (14)
Translational Vision Science & Technology (1)

Article Type

ARVO Annual Meeting Abstract (14)
Clinical Trials (1)

Topics

Eye Anatomy and Disorders (1)
Retina (1)
Translational Research (1)

Tags

diabetic macular edema (1)
eye (1)
inflammation (1)
injections (1)
plasma kallikrein (1)
safety (1)
surrogate endpoints (1)

Specify Date Range

From: To: Apply

Showing 1 – 15 of 15

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

AG-80308, a novel first-in-class ophthalmic solution for the treatment of dry eye disease

Janet K Cheetham; Sandy Lai; Tan Nguyen; Sunil S Patel; Scott M Whitcup; Madhu Cherukury

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2984.

ARVO Annual Meeting Abstract June 2024

The DAVIO 2 trial: a phase 2, randomized, double-masked, controlled multicenter study of EYP-1901 vs aflibercept in previously treated wet age-related macular degeneration

David Aaron Eichenbaum; Vrinda Hershberger; Sunil S Patel; Ashkan Michael Abbey; W Zachery Bridges; Arshad M. Khanani; Stephanie Ruggiero; Monica Roy; Jay S Duker; Dario A Paggiarino

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4401.

ARVO Annual Meeting Abstract June 2024

A multicenter, open-labeled, phase 2a study of AG-73305, a novel bi-specific Fc-fusion protein for the treatment of diabetic macular edema

Tan Nguyen; Sunil Patel; Janet K Cheetham; David S Boyer; Artemis Wu; Larry A Wheeler; Madhu Cherukury

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1759.

ARVO Annual Meeting Abstract June 2024

Post Hoc Analysis of a Phase 3 Trial on SB15 (Proposed Aflibercept Biosimilar): Assessment on Pre-to-Post Switching Efficacy and Safety in Neovascular Age-related Macular Degeneration

SriniVas R Sadda; Se Joon Woo; Mario Bradvica; Attila Vajas; Min Sagong; Jan Ernest; Jan Studnička; Miroslav Veith; Edward Wylegala; Sunil Patel; Cheolmin Yun; Inkyung Oh; Hyerin Jang; Taehyung Kim; Wooree Choi; Neil M Bressler

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3832.

ARVO Annual Meeting Abstract June 2023

The DAVIO trial: a phase 1, open-label, dose-escalation study of a single injection of EYP-1901 (vorolanib in Durasert ® platform) demonstrating reduced treatment burden in wet age-related macular degeneration

Ashkan Michael Abbey; Sunil S Patel; Mark Barakat; Vrinda S Hershberger; William Z Bridges; David Aaron Eichenbaum; David Lally; Philip P Storey; Monica Roy; Jay S Duker; Dario A Paggiarino

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):931.

ARVO Annual Meeting Abstract June 2023

Open-label Phase 2a study of AG-73305, a novel bi-specific Fc-fusion protein for the treatment of diabetic macular edema

Sunil Patel; Janet K Cheetham; Tan Nguyen; David S Boyer; Artemis Wu; Ben Chang; Larry A Wheeler; Madhu Cherukury

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2642.

Clinical Trials December 2021

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

PDF

Pravin U. Dugel; Arshad M. Khanani; Brian B. Berger; Sunil Patel; Mitchell Fineman; Glenn J. Jaffe; Petra Kozma-Wiebe; Jeffrey Heier
TAGS: diabetic macular edema, injections, plasma kallikrein, safety, inflammation, surrogate endpoints, eye
Trans. Vis. Sci. Tech.. 2021; 10(14):28. https://doi.org/10.1167/tvst.10.14.28

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2020

Updated Results of Phase 1b Study of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate with Extended Durability, in wAMD, DME, and RVO

Sunil S Patel; Daniel Janer; Bryce Miller; Jason S Ehrlich; Victor Perlroth; J. Pablo Velazquez-Martin

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4286.

ARVO Annual Meeting Abstract July 2019

Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate with extended durability

Sunil S Patel; Joel Naor; Almas Qudrat; Diana V Do; Desiree Buetelspacher; hong liang; D. Victor Perlroth

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3670.

ARVO Annual Meeting Abstract July 2018

Anti-VEGF/anti-angiopoietin-2 bispecific antibody RG7716 in diabetic macular edema: complete 36-week results from the phase 2, multicenter, randomized, active treatment-controlled BOULEVARD clinical trial

Sunil S Patel; Jayashree Sahni; Shamil Sadikhov; Meike Pauly-Evers; Piotr Szczesny; Robert Weikert

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1959.

ARVO Annual Meeting Abstract June 2017

Brimonidine Drug Delivery System (DDS) Generation 1 in patients with geographic atrophy: Post-hoc analysis of a phase 2 study

Baruch D Kuppermann; Sunil S Patel; David S Boyer; Albert J Augustin; William R Freeman; Thomas Kim; Kevin Kerr; Francisco J Lopez; Susan Schneider

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1924.

ARVO Annual Meeting Abstract June 2017

Patient-, caregiver-, and healthcare provider-reported burden of geographic atrophy

Sunil S Patel; Rishi P Singh; Jared S Nielsen; Jordana Schmier; Yamina Rajput

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1523.

ARVO Annual Meeting Abstract June 2015

A Phase 1 Safety Study of an Orally Available Tyrosine Kinase Inhibitor X-82 in Previously Treated Wet AMD Patients

Philip J Rosenfeld; Jason S Slakter; David S Boyer; David M Brown; Nauman A Chaudhry; Michael J Elman; Sunil S Patel; Denis O’Shaughnessy

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4804.

ARVO Annual Meeting Abstract June 2013

Truck Drivers Suffer Significant Economic Harm Due to Diabetic Macular Edema

Sunil Patel; Colleen Peters; Kristen Garcia; Angela Jaimes; Bryce Miller; Steven Kymes; Adam Turpcu

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2369.

ARVO Annual Meeting Abstract April 2011

Dexamethasone Intravitreal Implant (DEX Implant) Alone And As An Adjunct To Ranibizumab For The Treatment Of Choroidal Neovascularization (CNV) Secondary To Age-related Macular Degeneration (AMD)

Michael Singer; Sunil S. Patel; Harvey S. Uy; Ching-Chi Liu; Xiao-Yan Li; Scott M. Whitcup

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3536.

« Previous

Advertisement

Follow @ARVOiovs

IOVS Home
Issues
Topics
For Authors
About
- Editorial Board

Online ISSN: 1552-5783

Investigative Ophthalmology & Visual Science
Journal of Vision
Translational Vision Science & Technology

JOURNALS HOME
TOPICS
ABOUT ARVO JOURNALS

Copyright © 2025 Association for Research in Vision and Ophthalmology.

Access Provided By:
MIT Libraries

Forgot password?

To View More...

Purchase this article with an account.

Create an Account

or

Subscribe Now

×

×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept